Information Provided By: 
Fly News Breaks for October 27, 2016
CHE
Oct 27, 2016 | 07:38 EDT
Oppenheimer analyst Michael Wiederhorn says Chemed's results missed estimates due to a combination of weak high-acuity results and also likely mis-modeling by the Street. Nevertheless, the analyst believes this remains a "strong" company that will look to return to normal growth levels in 2017 as the reimbursement changes are annualized. He reiterates an Outperform rating and $155 price target on the shares.
News For CHE From the Last 2 Days
